CIViC Evidence Items

194 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline

BClinical — prospective trial or retrospective cohort study

CCase study — single case report or small case series

DPreclinical — in vitro or animal model data

EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

	Predictive	Diagnostic	Prognostic	Functional	Predispos.	Oncogenic
BCR::ABL1	323	11
BRAF	186	4	26	2		1
EGFR	248		12	3		2
EML4::ALK	64
ERBB2	142		2
FLT3	55	2	21
KIT	102	3	7
KRAS	159	4	24			4
PIK3CA	156		16	4
PTEN	53	1	3	1	2	1
TP53	52		40	100	2
VHL	5	2	3		635	15

Predictive:Links a variant to treatment response or resistance

Diagnostic:Supports or refutes a specific disease diagnosis

Prognostic:Informs disease progression or clinical outcome

Functional:Characterises the biological effect of a variant

Predisposing:Germline variant associated with cancer predisposition

Oncogenic:Characterises the variant's role in oncogenesis

Level	Gene	Variant	Type	Direction	Significance	Disease	Drugs	Source
D	TP53	L111R	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	H115Y	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	C124R	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	C135W	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	L139N	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	P152L	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	R158G	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	R158H	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	G266V	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	G266E	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	F270S	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
D	TP53	V272G	Functional	Does Not Support	Dominant Negative			Marutani et al., 1999
B	TP53	Mutation	Predictive	Supports	Sensitivity/Response	Cancer	VEGF/VEGFR Inhibitors	Wheler et al., 2016
B	TP53	Mutation	Prognostic	Supports	Poor Outcome	Adrenocortical Carcinoma		Sidhu et al., 2005
B	TP53	Deleterious Mutation	Predictive	Does Not Support	Sensitivity/Response	Lung Non-small Cell Carcinoma	Adjuvant Chemotherapy	Ma et al., 2016
B	TP53	Deleterious Mutation	Predictive	Supports	Sensitivity/Response	Sarcoma	Pazopanib	Koehler et al., 2016
E	TP53	P47S	Predictive	Supports	Resistance	Cancer	Cisplatin	Jennis et al., 2016
B	TP53	P72R	Prognostic	Does Not Support	Poor Outcome	Cervical Cancer		Klug et al., 2001
B	TP53	Mutation	Predictive	Supports	Sensitivity/Response	Chronic Lymphocytic Leukemia	Alemtuzumab	Lozanski et al., 2004
D	TP53	C238Y	Functional	Supports	Dominant Negative			Monti et al., 2011
C	TP53	R175H OR TP53 H193R	Predictive	Supports	Sensitivity/Response	Sarcoma	Pazopanib,Vorinostat	Fu et al., 2015
D	TP53	C242F	Functional	Supports	Loss of Function			Jordan et al., 2010
D	TP53	C242S	Functional	Supports	Loss of Function			Jordan et al., 2010
D	TP53	C242Y	Functional	Supports	Loss of Function			Jordan et al., 2010
D	TP53	E285K	Functional	Supports	Unaltered Function			Jordan et al., 2010
D	TP53	G154S	Functional	Supports	Loss of Function			Jordan et al., 2010
D	TP53	P152T	Functional	Supports	Dominant Negative			Monti et al., 2002
D	TP53	R156P	Functional	Supports	Dominant Negative			Monti et al., 2002
D	TP53	R181C	Functional	Supports	Dominant Negative			Monti et al., 2002
D	TP53	R181G	Functional	Supports	Dominant Negative			Monti et al., 2002
D	TP53	R181H	Functional	Supports	Dominant Negative			Monti et al., 2002
D	TP53	D259V	Functional	Supports	Dominant Negative			Monti et al., 2002
D	TP53	E286K	Functional	Supports	Dominant Negative			Monti et al., 2002
D	TP53	R283H	Functional	Supports	Dominant Negative			Monti et al., 2002
D	TP53	Y163N	Functional	Supports	Dominant Negative			Monti et al., 2002
D	TP53	L257P	Functional	Supports	Dominant Negative			Monti et al., 2002
C	TP53	R273C OR TP53 G245S OR TP53 R213*	Predictive	Supports	Sensitivity/Response	Colorectal Cancer	Vorinostat,Pazopanib	Fu et al., 2015
C	TP53	Mutation	Predictive	Supports	Resistance	Breast Cancer	Tamoxifen	Berns et al., 2000
C	TP53	Mutation	Predictive	Supports	Sensitivity/Response	Stomach Carcinoma	Cisplatin,Etoposide,Doxorubicin	Bataille et al., 2003
C	TP53	R273L	Predictive	Supports	Resistance	Ovarian Cancer	Carboplatin,Cisplatin	Reles et al., 2001
C	TP53	R175H	Predictive	Supports	Sensitivity/Response	Stomach Carcinoma	EAP Protocol	Bataille et al., 2003
C	TP53	Y234C	Predictive	Supports	Resistance	Ovarian Cancer	Carboplatin,Cisplatin	Reles et al., 2001
C	TP53	R282L	Predictive	Supports	Sensitivity/Response	Stomach Carcinoma	EAP Protocol	Bataille et al., 2003
C	TP53	R213P	Predictive	Supports	Sensitivity/Response	Stomach Carcinoma	EAP Protocol	Bataille et al., 2003

Page 4 of 4